Transcript
ReachMD Announcer:
You’re listening to a ReachMD medical industry feature, titled “Advanced Endometrial Carcinoma: A Look into Care Considerations”.
Voiceover:
This presentation has been created and paid for by Merck. The information in this presentation is intended for healthcare professionals in the United States and its territories, including Puerto Rico.
Medical Oncologist:
Tina, do you have a moment to discuss the treatment plan for the patient in room 7?
Nurse Practitioner:
Hi Dr. Jones. Yes, how can I help?
Medical Oncologist:
You may remember Linda; she was here a few months ago... age 57, diagnosed with stage IVB endometrial carcinoma with endometrioid histology and lung metastases.
Nurse Practitioner:
Oh yes, I remember her well! She was so sweet and was excited about her first grandchild being born. Do you have an update on Linda?
Medical Oncologist:
We started treatment with carboplatin and paclitaxel 3 months ago. Unfortunately, a CT shows disease progression with worsening lung metastases. She is not eligible for curative surgery or radiation. I see in her chart that she has an ECOG of 0. Comorbidities include obesity and hypertension.
Nurse Practitioner:
Let’s review her biomarker status. That might help us understand her treatment options.
Medical Oncologist:
Yes, that’s a great idea. I would typically treat a patient like Linda with chemotherapy, but I would like the multi-disciplinary team to weigh in to see if she may be eligible for a biomarker-directed treatment option.
Nurse Practitioner:
I’ll look forward to hearing the outcome of the team’s discussion so we can move forward to the next steps of Linda’s treatment plan.
Voiceover:
Explore more about a biomarker-directed treatment option for patients with certain types of advanced endometrial carcinoma.
Learn more at IsLindaEligible.com.
ReachMD Announcer:
This program was sponsored by Merck and Eisai. If you missed any part of this discussion, visit Industry Features on ReachMD.com, where you can Be Part of the Knowledge.
Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
US-END-00435 02/24
